Director Charles J Homcy sold 300,000 BBIO shares for $13.9M across 3 trades; reduces stake by 24.7%
Charles J Homcy, a director at BridgeBio Pharma, executed 3 separate sales totaling 300,000 shares (300.0K shares) for $13,912,442.76 ($13.9M) at a blended average price of $46.37, reducing his holdings from 1,216,674 shares (1.22M shares) to 916,674 shares (916.7K shares), a net reduction of 24.7% versus pre-transaction holdings. The sales occurred at prices ranging from $45.87 to $48.00 across August 8–11, 2025, while the company's stock currently trades at $49.09, near its 52-week high of $49.21. BridgeBio remains unprofitable, with a full-year net income of $-183,758,000.00 ($-183.8M) on revenue of $110,565,000.00 ($110.6M), though the company has shown extraordinary annual revenue growth of +2285.3% year-over-year. The sale represents a substantial reduction in directorial stake and occurs amid steep recent stock appreciation (+45.8% over 90 days), creating a noteworthy departure from established holdings at a valuation near all-time highs.